Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.

Japanese journal of clinical oncology - 1 Jan 2016

Ohno Makoto, Narita Yoshitaka, Miyakita Yasuji, Matsushita Yuko, Arita Hideyuki, Yonezawa Motoki, Yoshida Akihiko, Fukushima Shintaro, Takami Hirokazu, Ichimura Koichi, Shibui Soichiro

Abstract excerpt

OBJECTIVE: Glioblastomas with isocitrate dehydrogenase 1/2 mutations comprise a biologically distinct subgroup of glioblastomas. We studied isocitrate dehydrogenase 1/2 mutant glioblastomas at the clinical, molecular and radiological levels to define their clinical features, including the prognostic value of isocitrate dehydrogenase 1/2 mutations compared with isocitrate dehydrogenase 1/2 wild-type glioblastomas....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemoradiotherapy
Share to Chromosomes, Human, Pair 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dacarbazine

Share to Glioblastoma

Share to Guanine

Share to Isocitrate Dehydrogenase

Share to Kaplan-Meier Estimate

Share to Temozolomide

Source

Identifiers

PMID: 26603354
DOI: 10.1093/jjco/hyv170

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.PMID 26603354Read ↗

Molecular pathogenesis of IDH mutations in gliomas.Semantic proximity Read ↗

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.Semantic proximity Read ↗

IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy.Semantic proximity Read ↗

Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.Semantic proximity Read ↗

Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.Semantic proximity Read ↗

IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.Semantic proximity Read ↗

Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.Semantic proximity Read ↗

Genetic profile of astrocytic and oligodendroglial gliomas.Semantic proximity Read ↗

IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis.Semantic proximity Read ↗

Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcomeSemantic proximity Read ↗

New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status.Semantic proximity Read ↗

Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.